Introduction
A great majority of patients with non-Hodgkin's lymphoma (NHL) are elderly with a median age at diagnosis of about 65 years. 1 Older age is associated with poorer prognosis in NHL patients receiving conventional chemotherapy. [2] [3] Adding rituximab into CHOP-chemotherapy improves survival in patients with diffuse large B cell lymphoma (DLBCL). 4 Also, shortening the time interval of CHOP to 14 days may improve outcome in elderly patients. 5 However, a significant proportion of elderly patients with DLBCL do not attain a complete remission (CR) or experience a relapse after chemotherapy. Further, many elderly patients with mantle cell lymphoma, peripheral T-cell lymphoma or transformed follicular lymphoma have poor outcome.
High-dose chemotherapy supported by autologous stem cell transplantation (ASCT) has become standard of care in patients with relapsed chemosensitive histologically aggressive lymphoma. 6 ASCT may also be useful as a first-line therapy in selected patients with poor prognostic features 7 and is associated with promising outcome in patients with mantle cell lymphoma. 8 Although NHL is among the most common indications for ASCT, limited experience is available on the feasibility and efficacy of this approach in elderly lymphoma patients. In most trials patients460 years of age or at least465 years are excluded based on the age per se with the assumption that ASCT in elderly patients is associated with higher toxicity rate and hence limited clinical utility. Several small single centre series have been published on ASCT in NHL patients460 years of age. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The largest single centre series includes 53 patients transplanted in a long time period. 19 We have analysed in a nation-wide multicentre setting the feasibility and efficacy of ASCT in elderly NHL patients transplanted in 1994-2004.
Patients and methods

Patients
Altogether 88 NHL patients with 60 years of age or older received ASCT in six Finnish transplant centres between January 1990 and September 2004. Histopathological classification was based on REAL; immunohistochemical studies were available in all patients. The characteristics of the transplanted patients are summarised in Table 1 .
Staging
For all patients Ann Arbor staging system based on clinical examination, computed tomography and bone marrow examination (aspirate plus biopsy) was used. The same methods were used to assess the response to conventional chemotherapy as well as high-dose therapy.
Treatment before progenitor cell mobilisation Eighty-six patients had received chemotherapy before progenitor cell collection. The median number of chemotherapy courses was seven (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The most common chemotherapy regimen was CHOP or CHOP-like (n ¼ 66), followed by M-BACOD (n ¼ 9) and BFM (n ¼ 4). Two patients with T-cell prolymphocytic leukaemia had received only monoclonal anti-CD52 antibody before progenitor cell mobilisation.
Mobilisation of progenitor cells
Progenitor cell mobilisation was attempted in all patients. The most common regimen was cyclophosphamide (usually 4 mg/m 2 ) plus G-CSF (49 patients) followed by diseasespecific chemotherapy (36 patients) plus G-CSF. Three patients were mobilised with G-CSF alone or in combination with stem cell factor.
HDT protocols BEAC was the most commonly used high-dose regimen (n ¼ 49) followed by BEAM (n ¼ 34). Four patients received TBI-CY and one patient a modified regimen including carmustine, etoposide, cytosine arabinoside and fludarabine. Eighty-four patients (95%) received PB grafts (CD34 þ selected in 25 patients). Altogether 82 patients (93%) received G-CSF after the progenitor cell infusion.
Response criteria CR was defined as disappearance of all clinical and radiological evidence of lymphoma including normal marrow trephine biopsy in patients with previous BM involvement. Partial remission (PR) was defined as at least 50% reduction in tumour mass as assessed with clinical examination, computed tomography or trephine biopsy. Response to HDT was assessed 2-3 months after ASCT.
Statistical analysis
Overall survival (OS) and progression-free survival (PFS) were computed from the day of progenitor cell infusion according to the method of Kaplan-Meier. Relapse was regarded as a competing risk for treatment-related mortality (TRM). Early TRM was defined as a death within 100 days from ASCT from other reasons than lymphoma. For the comparison of frequencies between various groups w 2 test was used.
Results
Stem cell mobilisation and aphaeresis
The median peak B-CD34 þ count measured after the mobilisation was 42 Â 10 6 /l (8-244). With a median of two aphaeresis (1-6), a median of 3.6 Â 10 6 /kg CD34 þ cells was collected. In nine patients (10%), the minimum collection target (2 Â 10 6 /kg CD34 þ cells) was not reached with the first mobilisation. Two patients underwent a second mobilisation attempt with success, in three patients grafts containing 1.5-1.9 Â 10 6 /kg CD34 þ cells were considered sufficient to proceed to HDT. Four patients with failed mobilisation went on to marrow harvest.
Engraftment
Three patients died early and were thus not evaluable for engraftment. All other 85 patients engrafted. The median times to achieve neutrophils40.5 Â 10 9 /l and unsupported platelets420 Â 10 9 /l were 10 days (8-25) and 14 days (8-not reached) days, respectively. Toxicity of HDT Neutropenic fever (4381C) was observed in 82 patients (93%). Blood cultures were positive in 26 patients (29%).
The most common blood culture findings were Staphylococcus epidermidis (n ¼ 11), Streptococcus viridans (n ¼ 4), Klebsiella pneumoniae (n ¼ 3) and Enterobacter faecium (n ¼ 2). No cases of fungal sepsis were observed. Five patients had radiologically verified pneumonia. Excluding mucositis and diarrhoea, WHO grade III-IV toxicities included cardiac (n ¼ 7), pulmonary (n ¼ 4), liver (n ¼ 3) and septic shock (n ¼ 2). Five patients were treated for these complications in intensive care unit after ASCT.
Early treatment-related deaths Ten patients (11%) died from early treatment-related reasons. The median time to their death was 42 days (4-82) from ASCT. These patients are summarised in Table 2 .
Early TRM was higher in patients who received BEAM conditioning (18%) when compared to patients who received BEAC (9%), but the difference was not statistically significant. TRM was comparable in patients aged 60-64 years and those of 65 years or more (11 vs 12%). TRM was higher in patients transplanted after relapse (23%) than in patient transplanted in first CR or PR (7%), but the difference did not reach statistical significance. The early TRM was 10% in patients with DLBCL, 7% in patients with MCL, 13% in patients with FCL and 17% in patients with PTCL (P ¼ NS).
Late non-relapse deaths Until September 2005, altogether six patients (7%) have died from reasons other than lymphoma4100 days from ASCT. These patients are summarised in Table 3 . Combining early TRM and late non-relapse deaths, altogether 18% of the patients have died from other reasons than relapse or progression of lymphoma. The actuarial non-relapse mortality was 19% at 4 years (Figure 1 ).
Response and survival after HDT Ten patients (11%) died from early treatment-related reasons o100 d from ASCT and were thus not evaluable for treatment response. Altogether 75 patients (85%) achieved or maintained a complete remission after ASCT. Two patients achieved a partial remission and one patient was refractory to HDT.
The projected 2-year OS for the whole patient cohort was 63% and 5-year survival 44% (Figure 2) . The projected 5-year survival was 50% in patients with MCL, 38% in patients with DLBCL, 28% for FL and 20% in patients with PTCL ( Figure 3) .
With a median follow-up of 21 months for all patients, 32 patients (36%) have relapsed or progressed 1-70 months from ASCT (median 12 months). The projected PFS was 62% at 2 years and 45% at 5 years ( Figure 4) .
The median survival was 8 months from the diagnosis of relapse or progression (0-56 months). Eight patients (25%) are alive 3-47 months from relapse or progression. 
Discussion
This nation-wide multicentre analysis on the feasibility and efficacy of ASCT in elderly NHL patients includes a larger patient cohort than any previous study published to date. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] A relatively high early TRM especially in patients with relapsed NHL and those receiving BEAM were among the most important observations. Patients with MCL and DLBCL had a reasonable outcome, whereas in patients with PTCL the outcome was poor.
Until recently, elderly patients with NHL have been excluded from most clinical trials including HDT with ASCT due to anticipated high risks of toxicity. Consequently, also in clinical practice some hesitance has existed in regard to performing ASCT in patients more than 60 years of age. Small single centre series are likely to report highly selected patient groups and due to small patient numbers do not allow more detailed analysis of risk factors for TRM nor prognostic issues.
The early TRM in this series was 11% and late nonrelapse mortality 7% giving a non-relapse mortality of 18% for this patient cohort. This figure is almost the same (22%) as the figure reported by the Seattle group. 19 In other smaller series including patients with NHL, the early TRM ASCT in elderly NHL patients E Jantunen et al has varied from zero 16 to around 10 percent. 13, 14, 17, 20 For comparison, the early TRM was 3% among 464 NHL patients aged 16-59 years who received ASCT in the same Finnish transplant centres in 1990-2003 and were treated with the same protocols. We can thus conclude that ASCT is feasible in selected elderly NHL patients although TRM seems to be higher than reported in younger patients.
Besides feasibility, also efficacy is of prime importance in regard to applicability of ASCT in elderly lymphoma patients. Larger patient numbers in various histologic groups are needed for more detailed analysis of outcome; this might be possible for example based on EBMT registry data. Considering the larger patient groups of this analysis, the outcome was promising in patients with MCL and in some patients with DLBCL. Almost all patients with MCL received ASCT according to the prospective protocols of the Nordic Lymphoma Group (NLG). 8, 21 A registry analysis suggests improved survival in transplanted patients with MCL. 22 A randomised intergroup trial also suggested better PFS in ASCT recipients when compared to patients receiving CHOP-like regimen. 23 In our analysis, the early TRM was 7% in patients with MCL transplanted in first CR or PR, which seems to be acceptable in this disease provided that the outcome otherwise is reasonable.
In patients with DLBCL the issue of efficacy of ASCT is more complicated. Twelve of our patients received ASCT in first CR or PR due to poor prognostic factors. Although some studies 7,24-27 suggest benefits of ASCT over conventional chemotherapy in patients with histologically aggressive lymphoma, many other studies have failed to confirm these results. [28] [29] [30] [31] [32] Consequently, ASCT is not any longer commonly used as first-line therapy in this patient group. On the other hand, in patients with chemosensitive relapse, ASCT has been shown to be superior to conventional chemotherapy. 6 In our experience, the early TRM was as high as 18% in patients with relapsed DLBCL and the median OS was only 14 months in this patient group suggesting need for more effective approaches. A comparative US study suggested that PFS and OS of elderly patients (465 years) are comparable to younger patients who had received ASCT in chemosensitive relapse. 17 Inclusion of rituximab in the first-line protocols, 4 as well as more effective chemotherapy regimens 5 may decrease the number of relapses and thus need for ASCT in patients with DLBCL. The inclusion of rituximab into HDT protocols for relapsed DLBCL might improve the outcome of these patients.
Patient selection has an important impact on the results of HDT. This is especially the case in elderly patients partly due to their higher risks of treatment-related complications. Adequate organ function and chemosensitive lymphoma seem to be prerequisites for promising outcome. There may be also protocol-related issues. This retrospective analysis suggests that BEAM may be associated with higher early TRM than BEAC although the difference was not statistically significant. As mucositis and diarrhoea are major toxicities in patients receiving ASCT, aims to reduce mucosal toxicity might be associated with better outcome in elderly patients with NHL. At present, palifermin seems to be most promising agent in this respect, 33 but studies in elderly population are needed to show whether this agent can reduce toxicities associated with high-dose therapy in a clinically meaningful magnitude.
Is there any age limit for HDT in patients with NHL? Obviously individual variation is considerable in regard to toxicity of HDT also in elderly patients. The median age of the patients was only 63 years in this analysis. There were 17 patients with 65 years old or more and no patients were over 70 years of age. Although it might be concluded that ASCT is feasible up to age of 65 years by using blood progenitor cell support, minimal data are still available in patients more than 65 years of age.
To conclude, HDT with ASCT is feasible in selected elderly patients with NHL but TRM is considerable. Durable responses are observed in many patients suggesting that age of more than 60 years should not be used as exclusion criteria from ASCT. Considering increased toxicity of conventional high-dose regimens, testing of novel agents and regimens seems to be of importance also in this patient group.
